Oppenheimer analyst Steven Lichtman assigned a Buy rating to Zimmer Biomet Holdings (ZBH) today and set a price target of $173.00. The company’s shares closed last Friday at $163.61, close to its 52-week high of $165.93.
According to TipRanks.com, Lichtman is a 5-star analyst with an average return of 13.3% and a 58.0% success rate. Lichtman covers the Healthcare sector, focusing on stocks such as Merit Medical Systems, Integra Lifesciences, and Motus Gi Holdings.
Currently, the analyst consensus on Zimmer Biomet Holdings is a Strong Buy with an average price target of $171.68, which is a 1.0% upside from current levels. In a report issued on January 25, BTIG also maintained a Buy rating on the stock with a $173.00 price target.
See today’s analyst top recommended stocks >>
Based on Zimmer Biomet Holdings’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $1.93 billion and net profit of $243 million. In comparison, last year the company earned revenue of $1.89 billion and had a net profit of $431 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zimmer Biomet Holdings, Inc. provides musculoskeletal healthcare services. It designs, manufactures and markets orthopedic reconstructive products, sports medicine, biologics, extremities & trauma products, office based technologies, spine, craniomaxillofacial & thoracic products, dental implants and related surgical products. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Zimmer Biomet Holdings was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.